Allergan to Present New Data from its Eye Care Portfolio at ASCRS 2022

Allergan announced that it will present new data from its eye care portfolio at the 2022 ASCRS annual meeting being held April 22–26 in Washington, DC. Presentations will include new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia in adults, and Xen Gel Stent, a surgical implant designed to lower high eye pressure, FDA-cleared for refractory glaucoma patients.

"The data we'll be presenting at ASCRS showcases our continued commitment to innovate and provide additional treatment options for patients with eye conditions like presbyopia and glaucoma," said Michael R. Robinson, MD, vice president, global therapeutic area head, ophthalmology, AbbVie.

At the meeting, researchers will present new studies on the safety and efficacy of Vuity in a variety of settings. Notable data will include a post-hoc analysis evaluating the use of Vuity in participants with moderate to advanced presbyopia and a new analysis evaluating the onset of efficacy in participants with presbyopia. AbbVie will also present an analysis evaluating intermediate vision for presbyopia patients treated with Vuity.  

Additionally, new analyses from studies assessing the safety and efficacy of the Xen Gel Stent will be presented. The Xen Glaucoma Treatment System is indicated for the surgical management of refractory glaucoma, including cases where previous surgical treatment has failed; cases of primary open angle glaucoma; and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy. The Xen Gel Stent is FDA-cleared for insertion via an ab interno approach; ab externo insertion of Xen Gel Stent is investigational and the safety and efficacy of this approach have not been evaluated by the FDA.

A complete listing of the Allergan ASCRS 2022 Annual Meeting abstracts can be viewed at https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Home/0.

Details about Allergan's presentations are as follows:

*ASCRS Disclaimer: All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.